Mode
Text Size
Log in / Sign up

Papillary Thyroid Cancer

Part of Head and Neck Cancer

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Papillary Thyroid Cancer

6 trials tracked for Papillary Thyroid Cancer.

6Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 4 Phase 1 1 Other / NA 1
  1. Phase 2 Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer Completed
  2. Phase 2 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed
  3. Phase 2 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Completed
  4. Phase 2 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed
  5. Phase 1 Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Completed
  6. N/A Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Head and Neck Cancer

Related studies from across the Head and Neck Cancer family.

Hashimoto's thyroiditis functions as a dual-natured immune microenvironment in differentiated thyroid cancer
Rheumatology Sys. Review
Hashimoto's thyroiditis functions as a dual-natured immune microenvironment in differentiated thyroid cancer Hashimoto's thyroiditis may both help and hinder thyroid cancer
This narrative review explores the role of Hashimoto's thyroiditis (HT) in the immune microenvironment of differentiated thyroid cancer. The…
Hashimoto's thyroiditis can act as both a shield and a sword for thyroid cancer, depending on the specific immune environment of the patient…
Molecular testing reduces surgical resection rates for indeterminate thyroid nodules in Western and Asian cohorts
Oncology Meta-analysis
Molecular testing reduces surgical resection rates for indeterminate thyroid nodules in Western and Asian cohorts Molecular testing helps decide if surgery is needed for thyroid nodules
This meta-analysis of 127 studies evaluated the impact of molecular testing on surgical management and risk of malignancy for indeterminate …
Molecular testing can help doctors decide if surgery is necessary for thyroid nodules, showing different clinical roles in Western and Asian…
Vitamin D and gut microbiota interact to regulate immunity and improve bioavailability in thyroid disorders
Diabetes & Endocrinology Sys. Review
Vitamin D and gut microbiota interact to regulate immunity and improve bioavailability in thyroid disorders Vitamin D and gut health may help manage thyroid disorders
This systematic review explores the interplay between Vitamin D and gut microbiota in patients with thyroid disorders, including autoimmune …
New research highlights how vitamin D and gut bacteria work together to support the immune system in people with thyroid conditions.
Preoperatively detected PTEN alterations in thyroid nodules correlate with a 32.4% risk of invasive malignancy
ENT (Otolaryngology) Meta-analysis
Preoperatively detected PTEN alterations in thyroid nodules correlate with a 32.4% risk of invasive malignancy Molecular testing helps identify risk in thyroid nodules
This meta-analysis of 87 patients with Bethesda III/IV thyroid nodules identifies a 32.4% risk of invasive malignancy in those with preopera…
New molecular testing can help doctors identify the risk of cancer in thyroid nodules, providing a clearer picture for patients with uncerta…
Gut Microbiome and Metabolites May Modulate Thyroid Cancer Immunity and Treatment Response
Oncology Sys. Review
Gut Microbiome and Metabolites May Modulate Thyroid Cancer Immunity and Treatment Response Gut bacteria and metabolites may influence thyroid cancer treatment
This narrative review examines how gut dysbiosis, bacterial outer membrane components such as lipopolysaccharides, and metabolites including…
Your gut health might play a hidden role in how your body responds to thyroid cancer treatments and immune system interactions.
CEUS combined with AI or elastography improves diagnostic performance for malignant thyroid nodules
Diabetes & Endocrinology Meta-analysis
CEUS combined with AI or elastography improves diagnostic performance for malignant thyroid nodules Contrast-Enhanced Ultrasound Shows Promise for Identifying Thyroid Nodules
This network meta-analysis of 5022 thyroid nodules evaluated the diagnostic performance of contrast-enhanced ultrasound (CEUS) combined with…
New analysis shows that combining contrast-enhanced ultrasound with other imaging tools can help doctors better identify malignant thyroid n…
Sociodemographic, laboratory, and ultrasonographic factors are associated with malignancy risk in thyroid nodules
Diabetes & Endocrinology Meta-analysis
Sociodemographic, laboratory, and ultrasonographic factors are associated with malignancy risk in thyroid nodules Specific Factors Linked to Higher Risk in Thyroid Nodules
This systematic review and meta-analysis of 194 studies evaluated sociodemographic, laboratory, and ultrasound features to assess malignancy…
Certain factors like male sex and specific ultrasound features are linked to a higher risk of cancer in patients with thyroid nodules.
Plectin knockdown and troglitazone treatment inhibit growth and migration in papillary thyroid carcinoma cell lines
Allergy & Immunology Guideline
Plectin knockdown and troglitazone treatment inhibit growth and migration in papillary thyroid carcinoma cell lines Plectin and Troglitazone Show Promise in Thyroid Cancer
This guideline synthesizes preclinical data regarding plectin (PLEC) as a potential target in papillary thyroid carcinoma. The findings sugg…
Researchers found that plectin is elevated in papillary thyroid cancer and that troglitazone may fight it by targeting plectin.
Intraoperative frozen section shows 98.8% specificity but limited sensitivity for detecting malignancy in Bethesda III nodules
ENT (Otolaryngology) Sys. Review
Intraoperative frozen section shows 98.8% specificity but limited sensitivity for detecting malignancy in Bethesda III nodules Frozen Section Analysis Shows High Specificity for Thyroid Nodules
This systematic review and meta-analysis of 1,069 patients with thyroid nodules evaluates the diagnostic accuracy of intraoperative frozen s…
Intraoperative frozen section tests show high accuracy in identifying cancer in certain thyroid nodules, but results can vary significantly.
No established correlation exists between paragangliomas and cervical lymph node metastasis in papillary thyroid carcinoma
Oncology Sys. Review
No established correlation exists between paragangliomas and cervical lymph node metastasis in papillary thyroid carcinoma Distinguishing Between Thyroid Cancer and Paraganglioma for Better Diagnosis
This case report and literature review examines the relationship between paragangliomas and cervical lymph node metastasis in patients with …
Doctors must accurately distinguish between thyroid cancer and paragangliomas to ensure correct treatment plans and accurate patient prognos…
FNA-Tg and BRAF V600E analysis can rectify histopathological misdiagnosis of cervical lymph node metastasis
Orthopedics & Sports Medicine Meta-analysis
FNA-Tg and BRAF V600E analysis can rectify histopathological misdiagnosis of cervical lymph node metastasis Combined Testing Corrects Diagnosis of Thyroid Cancer Lymph Node Spread
This case report describes a 52-year-old female with papillary thyroid carcinoma where combined FNA-Tg and BRAF V600E analysis corrected a h…
A new testing method using FNA-Tg and BRAF V600E analysis helped correctly identify cancer spread in a patient with thyroid cancer.
Contrast-enhanced ultrasound shows 81.6% diagnostic accuracy for differentiating benign from malignant thyroid nodules
Diabetes & Endocrinology Meta-analysis
Contrast-enhanced ultrasound shows 81.6% diagnostic accuracy for differentiating benign from malignant thyroid nodules Contrast-enhanced ultrasound shows promise for thyroid nodule diagnosis
This meta-analysis of 54 CEUS studies evaluated the diagnostic performance of contrast-enhanced ultrasound for characterizing thyroid nodule…
A new analysis finds contrast-enhanced ultrasound is 78.6% sensitive and 82.6% specific for telling benign from malignant thyroid nodules.